Position in BBIO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$187,083,663
+$87,696,688 QoQ
Shares Held
2,519,306
+93.9% QoQ
Ownership
1.29%
of shares outstanding
% of Portfolio
0.85%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Polar Capital Holdings Plc holds $3,129,351,296 across 43 Biotechnology names. BBIO ranks #4 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | XENE |
Xenon Pharmaceuticals Inc.
|
4,405,312 | $256,168,892 | |
| 2 | ELVN |
Enliven Therapeutics, Inc.
|
5,065,933 | $198,584,573 | |
| 3 | NUVL |
Nuvalent, Inc.
|
1,831,253 | $187,611,869 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
This page
|
2,519,306 | $187,083,663 | |
| 5 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
289,310 | $151,445,105 | |
| 6 | ASND |
Ascendis Pharma A/S
|
651,712 | $149,066,085 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
192,546 | $148,768,741 | |
| 8 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
1,615,586 | $140,507,514 |
All Filings in BBIO
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $187,083,663 | 2,519,306 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $99,386,975 | 1,299,346 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $50,956,152 | 981,058 | Shares | Defined | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||